Specific Binding Peptides from Rv3632: A Strategy for BlockingMycobacterium tuberculosisEntry to Target Cells?

Author:

Sánchez-Barinas Christian David12,Ocampo Marisol12ORCID,Tabares Luisa12,Bermúdez Maritza12,Patarroyo Manuel Alfonso12ORCID,Patarroyo Manuel Elkin13

Affiliation:

1. Fundación Instituto de Inmunología de Colombia (FIDIC), Carrera 50 No. 26–20, 111321 Bogotá, Colombia

2. Universidad del Rosario, Carrera 24 No. 63C-69, 111321 Bogotá, Colombia

3. Universidad Nacional de Colombia, Carrera 45 No. 26-85, 11001 Bogotá, Colombia

Abstract

Tuberculosis is an infectious disease caused byMycobacterium tuberculosis(Mtb, i.e., the aetiological agent); the WHO has established this disease as high priority due to its ensuing mortality.Mtbuses a range of mechanisms for preventing its elimination by an infected host; new, viable alternatives for blocking the host-pathogen interaction are thus sought constantly. This article updates our laboratory’s systematic search for antigens using bioinformatics tools to clarify theMtbH37Rv Rv3632 protein’s topology and location. This article reports a C-terminal region consisting of peptides 39255 and 39256 (81Thr-Arg114) having high specific binding regarding two infection-related cell lines (A549 and U937); they inhibited mycobacterial entry to U937 cells in a concentration-dependent manner. Rv3632 forms part of the mycobacterial cell envelope, formed by six linear synthetic peptides. Circular dichroism enabled determining the protein’s secondary structure. It was also found that peptide 39254 (61Gly-Thr83) was a HABP for alveolar epithelial cells and inhibited mycobacteria entry to these cells regardless of concentration. Sera from active or latent tuberculosis patients did not recognise HABPs 39254 and 39256. These sequences represent a promising approach aiming at their ongoing modification and for including them when designing a multi-epitope, anti-tuberculosis vaccine.

Funder

Colombian Science, Technology and Innovation Institute “Francisco José de Caldas”

Publisher

Hindawi Limited

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3